Pacira Pharmaceuticals (PCRX) Shares are Down -2.91%

Pacira Pharmaceuticals (PCRX) : During the past 4 weeks, traders have been relatively bearish on Pacira Pharmaceuticals (PCRX), hence the stock is down -10.22% when compared to the S&P 500 during the same period. However, in the past 1 week, the selling of the stock is down by -3.4% relative to the S&P 500. The 4-week change in the price of the stock is -10.34% and the stock has fallen -2.91% in the past 1 week.

The stock has recorded a 20-day Moving Average of 8.21% and the 50-Day Moving Average is 0.54%.The 200 Day SMA reached 25.96%. Pacira Pharmaceuticals, Inc. has dropped 19.34% during the last 3-month period . Year-to-Date the stock performance stands at -49.16%.


Pacira Pharmaceuticals (NASDAQ:PCRX): The stock opened in the green at $40.53 on Friday, but the bulls found it difficult to push the prices higher. The stock reached a high of $40.53 and a low of $38.85 for the day. The stock did not find buyers even at the lows and closed at $39.04 recording a loss of -3.29%. 360,995 shares exchanged hands during the trading day. The stock had closed at $40.37 in the previous days trading.

Pacira Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company is focused on the development, commercialization and manufacture of pharmaceutical products, based on its DepoFoam drug delivery technology, primarily for use in hospitals and ambulatory surgery centers. Its primary focus lies in the development of non-opioid products for postsurgical pain control. DepoFoam is basis for the companys lead product candidate, EXPAREL, a liposome injection of bupivacaine, an amide-type local anesthetic indicated for infiltration into the surgical site to produce postsurgical analgesia. In addition to EXPAREL, DepoFoam is also the basis for its other commercial product, DepoCyt(e), which the Company manufactures for its commercial partners, as well as its other product candidates. The Companys other product candidates include DepoMeloxicam and DepoTranexamic Acid.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.